Intranasal administration of cationic liposomes enhanced granulocyte–macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity

Abstract

ObjectiveInfectious diseases remain a threat to human life. Vaccination against pathogenic microbes is a primary method of treatment as well as prevention of infectious diseases. Particularly mucosal vaccination is a promising approach to fight against most infectious diseases, because mucosal surfaces are a major point of entry for most pathogens. We recently developed an effective mucosal adjuvant of cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl] (DC-chol) (DOTAP/DC-chol liposomes). However, the mechanism(s) underlying the mucosal adjuvant effects exerted by the cationic liposomes have been unclear. In this study, we investigated the role of granulocyte–macrophage colony-stimulating factor (GM-CSF), which was reported to act as a mucosal adjuvant, on the mucosal adjuvant activities of DOTAP/DC-chol liposomes when administered intranasally to mice.ResultsHere, we show that, although intranasal vaccination with cationic liposomes in combination with antigenic protein elicited GM-CSF expression at the site of administration, blocking GM-CSF function by using an anti-GM-CSF neutralizing antibody did not alter antigen-specific antibody production induced by DOTAP/DC-chol liposomes, indicating that GM-CSF may not contribute to the mucosal adjuvant activity of the cationic liposomes when administered intranasally.Electronic supplementary materialThe online version of this article (10.1186/s13104-018-3591-3) contains supplementary material, which is available to authorized users.

Plant‐derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells

“…GM‐CSF also promotes IL‐6 secretion (Evans, Shultz, Dranoff, Fuller, & Kamdar, 1998), and accordingly IL‐6 levels were also elevated when cells were subjected to PBs. Both chemokines play a pivotal role in the initiation of a humoral response to antigenic proteins (Tada, Hidaka, Kiyono, Kunisawa, & Aramaki, 2018), and IL‐6 has been explored as a molecular adjuvant for mucosal vaccines (Rath et al, 2013; Su et al, 2008; Thompson & Staats, 2011). The observed cytokine release indicates the PB formulation's potential to enhance immunity and to exert an adjuvant effect, which is in agreement with the findings of Whitehead et al (2014) and Hofbauer et al (2016).…”

Application of nanotechnology in drug delivery systems for respiratory diseases (Review)

“…It is possible that the different cellular uptake mechanisms of cationic and anionic NPs might lead to different immune effects following pulmonary administration. Through animal experiments in mice, Tada et al ( 29 ) demonstrated that cationic liposomes induced higher antigen-specific antibody levels compared with anionic and neutral liposomes. Similarly, Fromen et al ( 30 ) reported that cationic NPs (~37 mV) conjugated with model antigen ovalbumin induced a higher level of antigen-specific IgG and local mucosal IgA in the plasma and bronchoalveolar lavage fluid (BALF) of mice after pulmonary immunization.…”

Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation against Streptococcus pneumoniae Infections in Mice

“…Further, the obtained samples were incubated for 1 h at 4 • C, and the serum sample was collected after centrifugation at 1200× g for 30 min. The nasal wash (200 µL of cold D-PBS), vaginal wash (100 µL of cold D-PBS), and bronchoalveolar lavage fluid (1000 µL of cold D-PBS) were collected [16,31,32]. The samples were stored at −80 • C until use.…”